RxDoctor Payments DataLook up a doctor →

Ala Ahmad, MD

Critical Care Medicine · St Petersburg, FLNPI 1356669196

Payments from drug & device makers

$177,102in general payments, 2019–2025

Across 467 payments — averaging $379.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$110K
  • GSK$54K
  • Boehringer Ingelheim$5K
  • AstraZeneca$1K
  • Intuitive Surgical$827
  • Insmed, Inc.$535
  • plus $5K from 42 others

What the payments were for

  • Speaking & faculty fees$52,60085%
  • Travel & lodging$4511%
  • Food & beverage$9,08815%
  • Education$1060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$177,102 in reported general payments places this provider in the 90th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida

Medicare billing

Part B allowed, 2024
$227,775
Medicare patients
513
Services billed
1,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter269$244,114
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr103$63,429
Breo ElliptaFluticasone/Vilanterol74$43,188
Stiolto RespimatTiotropium Br/Olodaterol Hcl40$27,623
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$21,790
Spiriva RespimatTiotropium Bromide27$16,974
Arnuity ElliptaFluticasone Furoate33$8,762
Incruse ElliptaUmeclidinium Bromide24$8,465
SymbicortBudesonide/Formoterol Fumarate18$5,384
Albuterol Sulfate HfaAlbuterol Sulfate136$3,213
Ventolin HfaAlbuterol Sulfate51$2,930
BreynaBudesonide/Formoterol Fumarate11$1,672
Wixela InhubFluticasone Propion/Salmeterol19$1,007
Montelukast Sodium69$415
Prednisone38$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta$54,249$367,957503 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$5,442$44,59767 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,084$27,17443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 618 critical care medicine providers in Florida.

Other critical care medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →